Sohail Ikram
Overview
Explore the profile of Sohail Ikram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rout A, Sharma A, Ikram S, Garg A
Catheter Cardiovasc Interv
. 2022 Dec;
101(2):299-307.
PMID: 36490229
Background: The optimal dual antiplatelet therapy (DAPT) duration and regimen in patients undergoing percutaneous coronary intervention (PCI) using current generation drug eluting stents (DES) is still unclear. Aims: To compare...
2.
Zheng S, Kassem K, Ikram S, Ganzel B, Ghafghazi S, Kalra D
JACC Case Rep
. 2022 Jul;
4(13):764-769.
PMID: 35818592
A 59-year-old man had angina and an abnormal perfusion scan. Work-up revealed 2 left main coronary arteries: the anomalous artery originated from the right coronary cusp and took an aberrant...
3.
Shah S, Ismail I, Raza M, Ikram S
J Community Hosp Intern Med Perspect
. 2021 Jul;
11(3):404-406.
PMID: 34234916
Coronary arteriovenous fistulas (CAF) are infrequent anatomic anomalies that establish a direct connection between coronary arteries and cardiac chambers. The reported incidence is extremely low and estimated at 0.002% in...
4.
Bolli R, Mitrani R, Hare J, Pepine C, Perin E, Willerson J, et al.
Eur J Heart Fail
. 2021 Apr;
23(4):661-674.
PMID: 33811444
Aims: CONCERT-HF is an NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial designed to determine whether treatment with autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs), given...
5.
Shah S, Ali A, Ikram S
Expert Rev Clin Pharmacol
. 2021 Mar;
14(5):523-525.
PMID: 33764842
No abstract available.
6.
Shah S, Ali A, Ikram S
Expert Rev Clin Pharmacol
. 2021 Mar;
14(4):407-409.
PMID: 33689561
No abstract available.
7.
Bolli R, Perin E, Willerson J, Yang P, Traverse J, Henry T, et al.
JACC CardioOncol
. 2021 Jan;
2(4):581-595.
PMID: 33403362
Background: Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach...
8.
Raza M, Ikram S, Williams N, Otero D, Barry N, Kelsey N, et al.
Methodist Debakey Cardiovasc J
. 2020 Jul;
16(2):158-161.
PMID: 32670477
The incidence of primary cardiac tumors is exceedingly rare, whereas secondary cardiac tumors are more common in the global population. Cardiac involvement is seen in approximately 18% of patients with...
9.
Khan M, Moustafa A, Azhar A, Khan A, Ikram S
Eur J Prev Cardiol
. 2020 May;
28(12):e25-e28.
PMID: 32469617
No abstract available.
10.
Khan M, Khan A, Khan A, Seo M, Yasmin F, Usman M, et al.
Catheter Cardiovasc Interv
. 2020 Mar;
96(4):E447-E454.
PMID: 32222063
Background: Whether revascularization should be performed as multivessel intervention at the time of index procedure (MV-index), staged procedure (MV-staged), or culprit only intervention (COI) in patients with multivessel disease (MVD)...